Vanda Pharmaceuticals is back in focus after a fair value price target update to US$14.90 from US$12.67, reflecting refreshed assumptions in analyst models. Recent research is split, with some ...
Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...
View Vanda Pharmaceuticals Inc. VNDA stock quote prices, financial information, real-time forecasts, and company news from CNN.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) ...
WASHINGTON, Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective ...
In recent months, Vanda Pharmaceuticals has been busy working to grow its commercial presence through its acquisition of Johnson & Johnson's Ponvory and its recent bipolar disorder approval for Fanapt ...
Six years ago, the FDA turned down an application by Vanda Pharma seeking approval to sell its sleep disorder therapy Hetlioz for jet lag. Now, it has won an appeals court judgment forcing the agency ...
WASHINGTON, Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...
The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...
WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® ...
Vanda asked Martin Makary, the Commissioner of the Food and Drug Administration, to review the decision made by Jacqueline Corrigan-Curay, the departing director of the FDA's Center for Drug ...
Hosted on MSN
Vanda a new buy at B. Riley on 'historic discount'
B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a valuation that is a "historic discount" and is "untenable." The firm has a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results